CTRI/2017/09/009939
Completed
Phase 4
A retrospective, single-center, study to evaluate safety and performance of the Evermine 50- 50μm Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery lesions.
Meril Life Sciences Pvt Ltd0 sites171 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Sponsor
- Meril Life Sciences Pvt Ltd
- Enrollment
- 171
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. All patients who have been treated with Evermine 50 EES.
- •2\. Patients who are contactable, willing to participate will be taken into the study by either signing voluntary informed consent form or by taking telephonic consent of patient.
Exclusion Criteria
- •1\. There are no exclusion criteria for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A prospective, single-centre study to investigate the role of Optical Coherence Tomography and fractional flow reserve for post coronary angioplasty stent optimisatioHealth Condition 1: I208- Other forms of angina pectorisCTRI/2021/04/032543PGIMER
Not yet recruiting
Not Applicable
A prospective, Single-Centre study to investigate the plaque characteristics of lesions in young Indian patients of =40 yearsHealth Condition 1: I248- Other forms of acute ischemic heart diseaseCTRI/2024/01/061165Dr Nityanand Tripathi
Active, not recruiting
Not Applicable
GONDOLA: Gonorrhoea detection using laboratory assessmentGonococcal infectionInfections and InfestationsISRCTN16307168orth Cumbria University Hospitals NHS Trust60
Recruiting
Not Applicable
sefulness of acetic acid NBI magnification endoscopy for colorectal tumorsJPRN-UMIN000045621Sendai City Medical Center Sendai Open Hospital Department of Gastroenterology300
Completed
Not Applicable
Retrospective monocentric cohort study to evaluate the efficacy and safety of Splentis for transvaginal sacrospinal fixation of the primary apical prolapseN81.4Uterovaginal prolapse, unspecifiedDRKS00021072Promedon GmbH110